Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Mallinckrodt has agreed to acquire Sucampo Pharmaceuticals, a Rockville, Md.-based drugmaker, for $1.2 billion. With the deal, Mallinckrodt will pick up two approved drugs: Amitiza, a treatment for various bowel diseases with 2016 sales of $456 million, and Rescula, a treatment for ocular hypertension and glaucoma with annual sales of about $9 million. Mallinckrodt CEO Mark Trudeau says the deal also bolsters the company’s rare disease drug pipeline with VTS-270, in development for Niemann-Pick disease type C1, and CPP-1X/sulindac, in development for familial adenomatous polyposis.
This article has been sent to the following recipient: